Menu

Interchangeability or substitution of biosimilars

Biosimilares/Investigación | Posted 27/05/2011 post-comment0 Post your comment

The interchangeability or substitution of biosimilars is a subject that differs somewhat between Europe and the US. These different approaches to biosimilars are discussed by Dr Mark McCamish and Dr Gillian Woollett in their published paper [1].

picture31

In the EU, EMA does not have the authority to designate biosimilars as being interchangeable with the reference product.

In the US, however, the Biologics Price Competition and Innovation Act gives the FDA the authority to designate a biosimilar as interchangeable with its reference product. This means that the biosimilar may be substituted for the originator product by the pharmacist without reference to the prescribing physician.

This automatic substitution, the authors feel, would enable biosimilars to be adopted much more rapidly. Thus increasing access for patients to these often life-changing medicines and reducing healthcare costs for both patients and governments.

According to Dr McCamish and Dr Woollett, a biosimilar product for which comparability is demonstrated should be interchangeable with its comparator, as is the case for conventional generics.

Related articles

Need for a global pathway for biosimilars

Regulatory approach to biosimilar development

Opportunities for biosimilar development

Comparability for biosimilar development

Worldwide biosimilar development

Global biosimilar market to grow to US$3.7 billion in 2015

US guidelines for biosimilars

US healthcare reform

Reference

1. McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209-17. doi:10.4161/mabs.3.2.15005

comment icon Comments (0)
Post your comment
Novedades

Innovent-Etana bevacizumab biosimilar approved in Indonesia

Ranibizumab biosimilar, FYB201, receives EMA recommendation

Foro latinoamericano
Español
map logo
General

American Academy of Ophthalmology biosimilars guidance details

Estado actual de los biosimilares de anticuerpos monoclonales aprobados en América Latina

Most viewed articles

Sobre GaBI

The best selling biotechnology drugs of 2008: the next biosimilars targets

Global biosimilars guideline development – EGA’s perspective

EU guidelines for biosimilars

Related content

Perspectiva de la regulación de biosimilares en América Latina para mejorar el acceso al tratamiento del cáncer

Directrices revisadas de la OMS para los biosimilares: antecedentes científicos

El impacto de las insulinas biosimilares en el gasto público brasileño

¿Son necesarios los estudios sistemáticos de intercambio para los biosimilares?

Related content
Perspectiva de la regulación de biosimilares en América Latina para mejorar el acceso al tratamiento del cáncer
Regulation-V13H16
Biosimilares/Investigación Posted 22/07/2022
Directrices revisadas de la OMS para los biosimilares: antecedentes científicos
Guidance V13F21
Biosimilares/Investigación Posted 08/07/2022
El impacto de las insulinas biosimilares en el gasto público brasileño
103 MD001949
Biosimilares/Investigación Posted 17/06/2022
¿Son necesarios los estudios sistemáticos de intercambio para los biosimilares?
Switching mAb Pfizer V18K30
Biosimilares/Investigación Posted 25/03/2022
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
The best selling biotechnology drugs of 2008: the next biosimilars targets
picture09
INICIO/Informes Posted 14/10/2009
Global biosimilars guideline development – EGA’s perspective
picture07
INICIO/Directrices Posted 28/09/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010